<img alt="" height="1" width="1" />Summer Street Initiates Coverage of Salix Pharmaceuticals (SLXP) with a BuyStreetInsider.com (subscription)Beyond 2010, we expect Xifaxan to receive approval in irritable bowel syndrome (IBS)...We forecast revenue will grow from $231MM in 2009 to $1088MM in 2016 ...<nobr>and more »</nobr> |